{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=4",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 20596,
    "total_pages": 2060,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T13:27:10.635Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02165202",
      "title": "Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 136,
      "start_date": "2014-10",
      "completion_date": "2017-03-09",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 2,
      "location_summary": "Newark, New Jersey • The Bronx, New York",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02165202"
    },
    {
      "nct_id": "NCT02293837",
      "title": "Tocilizumab (TCZ) in New-onset Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "New-onset Type 1 Diabetes Mellitus",
        "T1DM",
        "T1D"
      ],
      "interventions": [
        {
          "name": "Tocilizumab (TCZ)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 136,
      "start_date": "2015-03-12",
      "completion_date": "2020-08-31",
      "has_results": true,
      "last_update_posted_date": "2021-09-08",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293837"
    },
    {
      "nct_id": "NCT00101595",
      "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Leukemia, Lymphoblastic, Acute, Philadelphia-positive"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2005-01",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2011-04-14",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101595"
    },
    {
      "nct_id": "NCT00726375",
      "title": "The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Etanercept (Enbrel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 34,
      "start_date": "2008-05",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-01-05",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00726375"
    },
    {
      "nct_id": "NCT06458075",
      "title": "Intervention to Improve Communication and Medication Adherence in Lupus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "CO-LEAD",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 480,
      "start_date": "2024-07-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06458075"
    },
    {
      "nct_id": "NCT01410630",
      "title": "FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Large B Cell Diffuse Lymphoma"
      ],
      "interventions": [
        {
          "name": "FLT-PET/CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "FDG-PET/CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "FLT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 66,
      "start_date": "2017-09-07",
      "completion_date": "2019-10-04",
      "has_results": false,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Omaha, Nebraska • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01410630"
    },
    {
      "nct_id": "NCT00951028",
      "title": "Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "Depression",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Life-steps adherence treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2008-09",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-18",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Providence, Rhode Island",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00951028"
    },
    {
      "nct_id": "NCT07532265",
      "title": "A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Asthma"
      ],
      "interventions": [
        {
          "name": "Frevecitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kinaset Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 512,
      "start_date": "2026-07-16",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 14,
      "location_summary": "Lancaster, California • San Jose, California • Brandon, Florida + 11 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07532265"
    },
    {
      "nct_id": "NCT04737265",
      "title": "Pilot Study of an NTproBNP Guided Strategy of Cardioprotection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cardiotoxicity",
        "Toxicity Due to Chemotherapy",
        "Breast Cancer",
        "Lymphoma",
        "Cardiomyopathies",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Biomarker Guided Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2021-03-18",
      "completion_date": "2025-02-05",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Philadelphia, Pennsylvania • West Chester, Pennsylvania",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "West Chester",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04737265"
    },
    {
      "nct_id": "NCT02786511",
      "title": "Longterm Follow-up of Subjects Treated With bb2121",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2016-04-28",
      "completion_date": "2019-10-11",
      "has_results": false,
      "last_update_posted_date": "2020-01-22",
      "last_synced_at": "2026-10-17T13:27:10.635Z",
      "location_count": 9,
      "location_summary": "Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786511"
    }
  ]
}